Email updates

Keep up to date with the latest news and content from Critical Care and BioMed Central.

Open Access Highly Accessed Research

Persistent organ dysfunction plus death: a novel, composite outcome measure for critical care trials

Daren K Heyland13*, John Muscedere13, John Drover2, Xuran Jiang3, Andrew G Day3 and the Canadian Critical Care Trials Group

Author Affiliations

1 Department of Medicine, Queen's University, 76 Stuart Street, Kingston, ON K7L 2V7, Canada

2 Department of Surgery, Queen's University, 76 Stuart Street, Kingston, ON K7L 2V7, Canada

3 Clinical Evaluation Research Unit, Kingston General Hospital, Kingston, ON K7L 2V7, Canada

For all author emails, please log on.

Critical Care 2011, 15:R98  doi:10.1186/cc10110

Published: 18 March 2011

Abstract

Introduction

Due to resource limitations, few critical care interventions have been rigorously evaluated with adequately powered randomized clinical trials (RCTs). There is a need to improve the efficiency of RCTs in critical care so that more definitive high quality RCTs can be completed with the available resources. The objective of this study was to validate and demonstrate the utility of a novel composite outcome measure, persistent organ dysfunction (POD) plus death, for clinical trials of critically ill patients.

Methods

We performed a secondary analysis of a dataset from a prospective randomized trial involving 38 intensive care units (ICUs) in Canada, Europe, and the United States. We define POD as the persistence of organ dysfunction requiring supportive technologies during the convalescent phase of critical illness and it is present when a patient has an ongoing requirement for vasopressors, dialysis, or mechanical ventilation at the outcome assessments time points. In 600 patients enrolled in a randomized trial of nutrition therapy and followed prospectively for six months, we evaluated the prevalence of POD and its association with outcome.

Results

At 28 days, 2.3% of patients had circulatory failure, 13.7% had renal failure, 8.7% had respiratory failure, and 27.2% had died, for an overall prevalence of POD + death = 46.0%. Of survivors at Day 28, those with POD, compared to those without POD, had a higher mortality rate in the six-month follow-up period, had longer ICU and hospital stays, and a reduced quality of life at three months. Given these rates of POD + death and using a two-sided Chi-squared test at alpha = 0.05, we would require 616 patients per arm to detect a 25% relative risk reduction (RRR) in mortality, but only 286 per arm to detect the same RRR in POD + mortality.

Conclusions

POD + death may be a valid composite outcome measure and compared to mortality endpoints, may reduce the sample size requirements of clinical trials of critically ill patients. Further validation in larger clinical trials is required.